UBS Group AG Grows Stock Position in Avanos Medical, Inc. $AVNS

UBS Group AG boosted its stake in Avanos Medical, Inc. (NYSE:AVNS) by 7.9% in the fourth quarter, Holdings Channel reports. The fund owned 415,107 shares of the company’s stock after buying an additional 30,290 shares during the quarter. UBS Group AG’s holdings in Avanos Medical were worth $4,662,000 as of its most recent SEC filing.

A number of other institutional investors and hedge funds have also recently bought and sold shares of the stock. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. boosted its holdings in Avanos Medical by 4.3% in the 1st quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 26,955 shares of the company’s stock worth $386,000 after acquiring an additional 1,121 shares during the period. Azzad Asset Management Inc. ADV lifted its stake in shares of Avanos Medical by 3.0% in the third quarter. Azzad Asset Management Inc. ADV now owns 43,230 shares of the company’s stock worth $500,000 after acquiring an additional 1,240 shares in the last quarter. Federated Hermes Inc. lifted its stake in shares of Avanos Medical by 6.9% in the third quarter. Federated Hermes Inc. now owns 25,083 shares of the company’s stock worth $290,000 after acquiring an additional 1,612 shares in the last quarter. Russell Investments Group Ltd. lifted its stake in shares of Avanos Medical by 969.3% in the second quarter. Russell Investments Group Ltd. now owns 2,545 shares of the company’s stock worth $31,000 after acquiring an additional 2,307 shares in the last quarter. Finally, Cary Street Partners Financial LLC lifted its stake in shares of Avanos Medical by 17.1% in the third quarter. Cary Street Partners Financial LLC now owns 18,475 shares of the company’s stock worth $214,000 after acquiring an additional 2,700 shares in the last quarter. Hedge funds and other institutional investors own 95.17% of the company’s stock.

Avanos Medical Stock Down 0.2%

AVNS stock opened at $24.65 on Friday. Avanos Medical, Inc. has a twelve month low of $9.30 and a twelve month high of $24.91. The company has a current ratio of 2.48, a quick ratio of 1.40 and a debt-to-equity ratio of 0.11. The company has a market capitalization of $1.15 billion, a P/E ratio of -15.31 and a beta of 1.58. The firm has a 50 day simple moving average of $19.67 and a 200-day simple moving average of $15.01.

Avanos Medical (NYSE:AVNS) last released its quarterly earnings results on Tuesday, May 5th. The company reported $0.22 earnings per share for the quarter, topping analysts’ consensus estimates of $0.16 by $0.06. Avanos Medical had a negative net margin of 10.39% and a positive return on equity of 5.39%. The business had revenue of $182.20 million during the quarter, compared to the consensus estimate of $170.00 million. During the same quarter last year, the company earned $0.26 earnings per share. The business’s quarterly revenue was up 8.8% compared to the same quarter last year. On average, equities research analysts predict that Avanos Medical, Inc. will post 1.07 earnings per share for the current fiscal year.

Analyst Upgrades and Downgrades

Several equities research analysts have issued reports on the company. Zacks Research downgraded Avanos Medical from a “hold” rating to a “strong sell” rating in a report on Thursday, May 7th. Wall Street Zen downgraded shares of Avanos Medical from a “buy” rating to a “hold” rating in a research report on Saturday, April 18th. Finally, Weiss Ratings raised shares of Avanos Medical from a “sell (e+)” rating to a “sell (d-)” rating in a research report on Wednesday, April 22nd. Two equities research analysts have rated the stock with a Sell rating, According to data from MarketBeat, the company has a consensus rating of “Sell”.

Avanos Medical Company Profile

Avanos Medical is a global medical technology company that develops and markets a broad portfolio of medical devices intended to improve patient outcomes in hospital, outpatient and post-acute care settings. The company’s products focus on three core therapy areas—pain management, enteral feeding and respiratory care—designed to help clinicians manage post-operative pain, deliver nutrition support and assist breathing for patients across a variety of acute and chronic conditions.

In its pain management segment, Avanos offers both non-opioid drug delivery systems and cryoanalgesia devices, including ambulatory infusion pumps and cooled radiofrequency ablation platforms.